ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Esmya 5 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg of…

Slide 1Dose Escalating Safety Study of a New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, in Patients Undergoing Total Hip Replacement: BISTRO I Eriksson BI, Dahl…

Jean-Yves Reginster, Philippe Hainaut, Olivier Bruyère and Jean-Michel Dogné Jonathan Douxfils, Fanny Buckinx, François Mullier, Valentine Minet, Véronique Rabenda, Controlled…

Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program * Disclosure Information Kenneth J Rothman is an employee of RTI Health Solutions,…

The launch of a blockbuster brand Results of the 1st Phase of the International GLORIA-AF Registry Program: Regional Treatment Differences Before the Era of Novel Anticoagulants…

West Yorkshire Cardiovascular Network Recommendations for the Introduction of New Oral Anticoagulants July 2012 CONTENTS New Oral Anticoagulants for the Prevention of Stroke…

Dose Escalating Safety Study of a New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, in Patients Undergoing Total Hip Replacement: BISTRO I Eriksson BI, Dahl OE, Ahnfelt…

Anticoagulated patients and neuraxial anaesthesia Dr.Srinivas Kallam Consultant anaesthetist, University Hospitals Leicester NHS trust introduction The widespread use of…